|
1
|
Versteijne E, van Dam JL, Suker M, Janssen
QP, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA,
Buijsen J, Busch OR, et al: Neoadjuvant chemoradiotherapy versus
upfront surgery for resectable and borderline resectable pancreatic
cancer: Long-term results of the Dutch randomized PREOPANC trial. J
Clin Oncol. 40:1220–1230. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Truty MJ, Kendrick ML, Nagorney DM, Smoot
RL, Cleary SP, Graham RP, Goenka AH, Hallemeier CL, Haddock MG,
Harmsen WS, et al: Factors predicting response, perioperative
outcomes, and survival following total neoadjuvant therapy for
borderline/locally advanced pancreatic cancer. Ann Surg.
273:341–349. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu J and Cai J: Dilemma and challenge of
immunotherapy for pancreatic cancer. Dig Dis Sci. 66:359–368. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zong L, Mo S, Sun Z, Lu Z, Yu S, Chen J
and Xiang Y: Analysis of the immune checkpoint V-domain
Ig-containing suppressor of T-cell activation (VISTA) in
endometrial cancer. Mod Pathol. 35:266–273. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ortega MA, Fraile-Martinez O, Pekarek L,
Garcia-Montero C, Alvarez-Mon MA, Castellanos AJ, García-Honduvilla
N, Buján J, Alvarez-Mon M, Sáez MA, et al: Oxidative stress markers
are associated with a poor prognosis in patients with pancreatic
cancer. Antioxidants (Basel). 11:7592022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fucikova J, Kepp O, Kasikova L, Petroni G,
Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G and Galluzzi L:
Detection of immunogenic cell death and its relevance for cancer
therapy. Cell Death Dis. 11:10132020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim R and Kin T: Current and future
therapies for immunogenic cell death and related molecules to
potentially cure primary breast cancer. Cancers (Basel).
13:47562021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hayashi K, Nikolos F and Chan KS:
Inhibitory DAMPs in immunogenic cell death and its clinical
implications. Cell Stress. 5:52–54. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang S, Tang W, Azizian A, Gaedcke J,
Ströbel P, Wang L, Cawley H, Ohara Y, Valenzuela P, Zhang L, et al:
Dysregulation of HNF1B/Clusterin axis enhances disease progression
in a highly aggressive subset of pancreatic cancer patients.
Carcinogenesis. 43:1198–1210. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang X, Wu S, Liu F, Ke D, Wang X, Pan D,
Xu W, Zhou L and He W: An immunogenic cell death-related
classification predicts prognosis and response to immunotherapy in
head and neck squamous cell carcinoma. Front Immunol.
12:7814662021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garg AD, De Ruysscher D and Agostinis P:
Immunological metagene signatures derived from immunogenic cancer
cell death associate with improved survival of patients with lung,
breast or ovarian malignancies: A large-scale meta-analysis.
Oncoimmunology. 5:e10699382015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ahn HR, Baek GO, Yoon MG, Son JA, You D,
Yoon JH, Cho HJ, Kim SS, Cheong JY and Eun JW: HMBS is the most
suitable reference gene for RT-qPCR in human HCC tissues and blood
samples. Oncol Lett. 22:7912021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Grünwald BT, Devisme A, Andrieux G, Vyas
F, Aliar K, McCloskey CW, Macklin A, Jang GH, Denroche R, Romero
JM, et al: Spatially confined sub-tumor microenvironments in
pancreatic cancer. Cell. 184:5577–5592.e18. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pekarek L, Fraile-Martinez O,
Garcia-Montero C, Alvarez-Mon MA, Acero J, Ruiz-Llorente L,
García-Honduvilla N, Albillos A, Buján J, Alvarez-Mon M, et al:
Towards an updated view on the clinical management of pancreatic
adenocarcinoma: Current and future perspectives. Oncol Lett.
22:8092021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fan JQ, Wang MF, Chen HL, Shang D, Das JK
and Song J: Current advances and outlooks in immunotherapy for
pancreatic ductal adenocarcinoma. Mol Cancer. 19:322020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reiss KA, Mick R, O'Hara MH, Teitelbaum U,
Karasic TB, Schneider C, Cowden S, Southwell T, Romeo J, Izgur N,
et al: Phase II study of maintenance rucaparib in patients with
platinum-sensitive advanced pancreatic cancer and a pathogenic
germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin
Oncol. 39:2497–2505. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Parikh AR, Szabolcs A, Allen JN, Clark JW,
Wo JY, Raabe M, Thel H, Hoyos D, Mehta A, Arshad S, et al:
Radiation therapy enhances immunotherapy response in microsatellite
stable colorectal and pancreatic adenocarcinoma in a phase II
trial. Nat Cancer. 2:1124–1135. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pekarek L, Fraile-Martinez O,
Garcia-Montero C, Saez MA, Barquero-Pozanco I, Del Hierro-Marlasca
L, de Castro Martinez P, Romero-Bazán A, Alvarez-Mon MA, Monserrat
J, et al: Clinical applications of classical and novel biological
markers of pancreatic cancer. Cancers (Basel). 14:18662022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jentho E and Weis S: DAMPs and innate
immune training. Front Immunol. 12:6995632021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jardim DL, Goodman A, de Melo Gagliato D
and Kurzrock R: The challenges of tumor mutational burden as an
immunotherapy biomarker. Cancer Cell. 39:154–173. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu YT and Sun ZJ: Turning cold tumors
into hot tumors by improving T-cell infiltration. Theranostics.
11:5365–5386. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang X, Lao M, Xu J, Duan Y, Yang H, Li
M, Ying H, He L, Sun K, Guo C, et al: Combination cancer
immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces
immunosuppressive effects in the microenvironment of pancreatic
tumors. J Immunother Cancer. 10:e0039822022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang X, Wang L, Mo Q, Dong Y, Wang G and
Ji A: Changes of Th17/Treg cell and related cytokines in pancreatic
cancer patients. Int J Clin Exp Pathol. 8:5702–5708.
2015.PubMed/NCBI
|
|
24
|
Gabitova-Cornell L, Surumbayeva A, Peri S,
Franco-Barraza J, Restifo D, Weitz N, Ogier C, Goldman AR, Hartman
TR, Francescone R, et al: Cholesterol pathway inhibition induces
TGF-β signaling to promote basal differentiation in pancreatic
cancer. Cancer Cell. 38:567–583.e11. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Angelova AL, Grekova SP, Heller A,
Kuhlmann O, Soyka E, Giese T, Aprahamian M, Bour G, Rüffer S,
Cziepluch C, et al: Complementary induction of immunogenic cell
death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic
cancer. J Virol. 88:5263–5276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hong W, Gu Y, Guan R, Xie D, Zhou H and Yu
M: Pan-cancer analysis of the CASP gene family in relation to
survival, tumor-infiltrating immune cells and therapeutic targets.
Genomics. 112:4304–4315. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Q, Pu N, Yin H, Zhang J, Zhao G, Lou
W and Wu W: CD73 acts as a prognostic biomarker and promotes
progression and immune escape in pancreatic cancer. J Cell Mol Med.
24:8674–8686. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
King RJ, Shukla SK, He C, Vernucci E,
Thakur R, Attri KS, Dasgupta A, Chaika NV, Mulder SE, Abrego J, et
al: CD73 induces GM-CSF/MDSC-mediated suppression of T cells to
accelerate pancreatic cancer pathogenesis. Oncogene. 41:971–982.
2022. View Article : Google Scholar : PubMed/NCBI
|
